|Bid||40.36 x 1000|
|Ask||40.62 x 800|
|Day's Range||40.19 - 41.26|
|52 Week Range||37.59 - 79.50|
|Beta (5Y Monthly)||0.39|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 08, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||70.33|
Subscribe to Yahoo Finance Plus to view Fair Value for ENTA
WATERTOWN, Mass., March 14, 2023--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced new data supporting the potential of EDP-235 for the treatment of COVID-19, which are being presented at the 36th International Conference on Antiviral Research (ICAR) being held March 13-17, 2023 at the Centre de Congrès de Lyon (Lyon Convention Center) in Lyon, France. The company will have one ora
WATERTOWN, Mass., March 07, 2023--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 10:00 a.m. ET.
Enanta Pharmaceuticals ( NASDAQ:ENTA ) First Quarter 2023 Results Key Financial Results Revenue: US$23.6m (down 15...